ClinicalTrials.gov
ClinicalTrials.gov Menu

Cell Proliferation in Pulmonary Hypertension. FDG-PET Comparison Between Patients and Healthy Subjects (PROCLAIM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02886793
Recruitment Status : Not yet recruiting
First Posted : September 1, 2016
Last Update Posted : September 1, 2016
Sponsor:
Information provided by (Responsible Party):
Joan Albert Barbera Mir, Hospital Clinic of Barcelona

Brief Summary:

Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are serious diseases with poor prognosis despite recent advances. Currently, pulmonary hypertension (PH) is considered a cell proliferative disorder, which has not been adequately characterized due to the lack of markers. A better understanding of the mechanisms that regulate this proliferative disorder will allow the identification of new therapeutic targets for HP.

The objective of the project is to identify cell proliferative processes in severe forms of PH. Patients with PAH (n=20), CTEPH (n=20) and healthy controls (n=20) will undergo characterization of microRNAs (miRNAs) contained within circulating microparticles (MPs) analysis and mitochondrial functionality and FDG-PET to compare cell metabolism in the lungs and the right ventricle between patients and controls.


Condition or disease Intervention/treatment Phase
Pulmonary Hypertension Drug: fludeoxyglucose Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Cell Proliferation in Pulmonary Hypertension. FDG-PET Comparison Between Patients and Healthy Subjects
Study Start Date : June 2016
Estimated Primary Completion Date : May 2018
Estimated Study Completion Date : May 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: FDG
all patients will undergo a PET scan and will receive 18F fludeoxyglucose
Drug: fludeoxyglucose
Other Name: FDG




Primary Outcome Measures :
  1. FDG uptake in lung parenchyma [ Time Frame: 1 hour ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Patients with PAH:

    • Hemodynamic diagnosis of precapillary pulmonary hypertension: PAPm ≥25 mmHg, PCWP ≤15 mmHg
    • Exclusion of group 2,3,4 or 5
  2. Patients with CTEPH:

    • Hemodynamic diagnosis of precapillary pulmonary hypertension: PAPm ≥25 mmHg, PCWP ≤15 mmHg
    • Persistence of thrombotic perfusion defects on pulmonary scintigraphy or angioCT, after 3 months or more of correct anticoagulant therapy
  3. Healthy subjects

    • No known disease or condition
    • Normal lung function, chest x-ray, EKG and blood chemistry and haematology

Exclusion Criteria:

  • Severe comorbidity.
  • Pulmonary, pleural or rib cage disease interfering with FDG-PET acquisition
  • Malignancy with exception of basocellular carcinoma
  • Current smoker or former smoker (last 10 years or more than 10-year-pack).
  • Pregnant or lactating women Hyperglycemia (fasting above 200 mg/dL)
  • Hypersensitivity to the product or its excipients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02886793


Contacts
Contact: Joan Albert Barberà, MD, PhD +34932275400 jbarbera@clinic.cat

Sponsors and Collaborators
Joan Albert Barbera Mir

Responsible Party: Joan Albert Barbera Mir, Dr, Hospital Clinic of Barcelona
ClinicalTrials.gov Identifier: NCT02886793     History of Changes
Other Study ID Numbers: 2016-000347-14
First Posted: September 1, 2016    Key Record Dates
Last Update Posted: September 1, 2016
Last Verified: August 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Hypertension
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases